Brief: OSE Immunotherapeutics, Nantes University Hospital Initiate Phase 1/2 Clinical Trial To Evaluate CD28 Antagonist FR104

Ose Immunotherapeutics SA

03/12/2020 17:28

Dec 3 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS AND NANTES UNIVERSITY HOSPITAL
ANNOUNCE
INITIATION OF A PHASE 1/2 CLINICAL TRIAL TO EVALUATE CD28
ANTAGONIST FR104 IN PATIENTS UNDERGOING RENAL TRANSPLANTATION
    * UNIVERSITY HOSPITAL OF NANTES WILL SPONSOR AND CONDUCT
CLINICAL
TRIAL
    * POST-TRANSPLANT IMMUNE RESPONSE IS A KEY THERAPEUTIC ISSUE
FOR
PATIENTS AND A NEW DEVELOPMENT INDICATION FOR FR104
    * OSE IMMUNOTHERAPEUTICS WILL PROVIDE ITS FR104 PRODUCT

Source text for Eikon:  ID:nBw7mr4wma 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))